Navigation Links
HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
Date:8/8/2011

FRAMINGHAM, Mass. and SYDNEY, Aug. 8, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Canaccord Genuity 31st Annual Growth Conference at 9:00 a.m. U.S. Eastern Time on Thursday, August 11, 2011.  The conference is being held August 9-11, 2011 at The InterContinental Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
2. HeartWare to Report Financial Results for Second Quarter of 2011
3. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
4. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
5. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
6. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
7. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
8. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
9. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
10. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
11. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no secret that aging ... to a host of health issues, including urinary incontinence. However, results published in ... that good overall muscle strength in older women, particularly in the abdominal and ...
(Date:2/27/2017)... ... , ... The threat of nuclear warfare has long plagued this world. In ... underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot started ... Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, N. ... ) has disclosed that despite scientific studies, the Center for Disease Control ( CDC ... Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single volume ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top ... and genders. And the need for advanced services is growing. , Project WE ... care program, in collaboration with their non-profit partners in their fight against cancer and ...
(Date:2/26/2017)... New York, New York (PRWEB) , ... February ... ... of luxury baby products for wholesale distribution in North America, today announced it ... established online sites. The company, which prides itself on crafting quality and unique ...
Breaking Medicine News(10 mins):